Biocells (Beijing) Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Series B2

  • Investors
  • 8

Biocells (Beijing) General Information

Description

Developer of tumor immunotherapy technologies designed to assist cancer patients in their treatment. The company's technologies focus on the field of neurological diseases and are aimed at biological treatment of tumors and nerves and prevention of strokes, hemorrhagic stroke and cerebral edema, providing cancer patients with immune cell therapy that aids in reducing post-operative recurrence, extending tumor-bearing survival, and lessening the discomfort of radiotherapy and chemotherapy.

Contact Information

Website
www.biocells.cn
Formerly Known As
Beijing Yukun Tiankang Biotechnology Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 301, 3rd Floor, Building 5, No. 23 Tianrong Street, Daxing Biomedicine Industry Base
  • Zhongguancun Science Park, Daxing District
  • Beijing, 102629
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 301, 3rd Floor, Building 5, No. 23 Tianrong Street, Daxing Biomedicine Industry Base
  • Zhongguancun Science Park, Daxing District
  • Beijing, 102629
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biocells (Beijing) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B2) 16-Jul-2024 Completed Generating Revenue
6. Later Stage VC (Series B1) 15-Sep-2023 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 20-Jul-2023 Completed Clinical Trials - General
4. Later Stage VC (Series A) 18-Sep-2021 Completed Clinical Trials - General
3. Secondary Transaction - Private 18-May-2021 Completed Clinical Trials - General
2. Later Stage VC 26-Jun-2019 Completed Clinical Trials - General
1. Later Stage VC 23-Feb-2018 Completed Clinical Trials - General
To view Biocells (Beijing)’s complete valuation and funding history, request access »

Biocells (Beijing) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Biocells (Beijing)’s complete cap table history, request access »

Biocells (Beijing) Patents

Biocells (Beijing) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026086901-A1 Polypeptide pharmaceutical composition for treating nervous system diseases and use thereof Pending 25-Oct-2024
WO-2026001614-A1 Sulfonylurea compound and use thereof Pending 26-Jun-2024
AU-2024412128-A1 Pharmaceutically acceptable salt of polypeptide and use thereof Pending 27-Dec-2023
EP-4834916-A1 Pharmaceutically acceptable salt of polypeptide and use thereof Pending 27-Dec-2023
WO-2025139301-A1 Pharmaceutically acceptable salt of polypeptide and use thereof Inactive 27-Dec-2023 C07K7/08
To view Biocells (Beijing)’s complete patent history, request access »

Biocells (Beijing) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biocells (Beijing) Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Orinno Capital Venture Capital Minority
Green Pine Capital Partners Venture Capital Minority
San Nuo Technology Corporation Minority
Xiamen Hi-Tech Innovation Center Venture Capital Minority
Everbright Financial Holding Asset Management Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Biocells (Beijing) FAQs

  • When was Biocells (Beijing) founded?

    Biocells (Beijing) was founded in 2009.

  • Where is Biocells (Beijing) headquartered?

    Biocells (Beijing) is headquartered in Beijing, China.

  • What is the size of Biocells (Beijing)?

    Biocells (Beijing) has 30 total employees.

  • What industry is Biocells (Beijing) in?

    Biocells (Beijing)’s primary industry is Drug Discovery.

  • Is Biocells (Beijing) a private or public company?

    Biocells (Beijing) is a Private company.

  • What is Biocells (Beijing)’s current revenue?

    The current revenue for Biocells (Beijing) is .

  • Who are Biocells (Beijing)’s investors?

    Orinno Capital, Green Pine Capital Partners, San Nuo Technology, Xiamen Hi-Tech Innovation Center, and Everbright Financial Holding Asset Management are 5 of 8 investors who have invested in Biocells (Beijing).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process